Diabetic ketoacidosis (DKA) is an acutely life-threatening complication of diabetes mellitus that occurs predominantly in type 1 diabetes, but is also increasingly occurring in people with type 2 diabetes. A special form is euglycemic DKA, which mainly occurs during therapy with SGLT2 inhibitors. Even though it has become rare and the mortality rate is now only just over 1%, these deaths are usually preventable. Timely diagnosis, standardized treatment protocols and, above all, prophylaxis are crucial for the prognosis.
Autoren
- Toralf Schwarz
Publikation
- CARDIOVASC
Related Topics
You May Also Like
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Across All Types of Cancer
Four-Legged Medical Assistants – Therapy Dogs in Clinical Settings
- Obesity: More than half of those affected have fatty liver disease
From screening to multimodal intervention with GLP-1-RA or resmetirom
- Innovative Oral Treatment Options for Psoriasis: Icotrokinra and Zasocitinib
First-class immunomodulation combined with convenience—the data available so far is convincing
- Preclinical Study on a Special Ginkgo biloba Extract
What role do proanthocyanidins play?
- Myasthenia gravis: immunomodulatory therapies for long-term treatment
Expanded Possibilities Thanks to Innovative Classes of Active Ingredients
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Plastic surgery and reconstructive microsurgery for DFS